KRT19 and metabolic dysfunction-associated steatotic liver disease: In light of the known expansion of cholangiocytes that occurs in MASLD in humans and mouse models (25–29) and the approximately threefold reduction in the cholangiocyte cell type association score elicited by DB treatment (Fig. 4A), we further investigated this finding by immunohistochemistry for cholangiocyte marker KRT19 in cryosections prepared from Western diet-fed vehicle- and DB-treated mouse livers.